facebook
twitter
rss
account
search
search
 

Carl Icahn gets control of Imclone Systems

Oct. 25, 2006 at 8:45 AM   |   Comments

NEW YORK, Oct. 25 (UPI) -- Activist investor Carl Icahn has been named the chairman of ImClone Systems Inc. after a lengthy battle for control of the U.S. pharmaceutical company.

Icahn said he would immediately launch a search for a chief executive with biotechnology experience and push the company's troubled Erbitux medicine.

The board also said Wednesday that Joseph L. Fischer has resigned as interim chief executive, effective Tuesday. In addition three board members will not stand for re-election: Dr. Vincent T. DeVita, Jr., John A. Fazio and William R. Miller.

Further, all director fees are being waived for six months and all option grants are being waived for the next year.

"The board fees and option grants at ImClone have been egregious, especially in light of the fact that shares have declined from a high of $86 to the current price of $30 in the past three years," said Icahn. "The options given to directors in corporate America have become disturbingly unrealistic, given that there is little correlation between the number of options granted and the performance of the companies being governed."

Topics: Carl Icahn
© 2006 United Press International, Inc. All Rights Reserved. Any reproduction, republication, redistribution and/or modification of any UPI content is expressly prohibited without UPI's prior written consent.
Recommended UPI Stories
Featured UPI Collection
trending
Notable deaths of 2014 [PHOTOS]

Notable deaths of 2014 [PHOTOS]

Most Popular
1
Deloitte: App downloads dwindle, 1 in 3 users disinterested
2
Iran wants to develop mini-LNG plants
3
AESA radar integrated into new F-16V
4
Europe could learn from U.S. shale success
5
GenDyn to study new guidance system for ICBMs
Trending News
Video
x
Feedback